Abstract

This invention relates to the use of nitroalkene derivatives for the treatment of neurodegenerative conditions in mammals in which neuroinflammation is a contributing factor, such as in amyotrophic lateral sclerosis (ALS).

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present disclosure relates to a method of enzymatically repairing RNAs that are nicked or at least partially cleaved. The method comprises providing a biological sample containing RNAs that are nicked or at least partially cleaved; purifying the nicked or at least partially cleaved RNAs contained in the biological sample, under a non-denaturing condition, to remove non-RNA components; and treating the purified RNAs with at least one of the following: (i) one or more enzymes that exhibit the activity of an RNA 3' phosphatase or cyclic phosphatase and the activity of an RNA 5' kinase, and an RNA ligase, or (ii) a 3'-5' RNA ligase, thereby forming repaired RNAs from the nicked or at least partially cleaved RNA. The present disclosure also relates to a method of detecting RNAs by enzymatically repairing RNAs that are nicked or at least partially cleaved, and detecting the repaired RNAs.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6874 - Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation [SBH]
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

The present disclosure relates to a method of enzymatically repairing RNAs that are nicked or at least partially cleaved. The method comprises providing a biological sample containing RNAs that are nicked or at least partially cleaved; purifying the nicked or at least partially cleaved RNAs contained in the biological sample, under a non-denaturing condition, to remove non-RNA components; and treating the purified RNAs with at least one of the following: (i) one or more enzymes that exhibit the activity of an RNA 3′ phosphatase or cyclic phosphatase and the activity of an RNA 5′ kinase, and an RNA ligase, or (ii) a 3′-5′ RNA ligase, thereby forming repaired RNAs from the nicked or at least partially cleaved RNA. The present disclosure also relates to a method of detecting RNAs by enzymatically repairing RNAs that are nicked or at least partially cleaved, and detecting the repaired RNAs.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

A method of estimating speech intelligibility is disclosed. The method comprises the steps of providing at least a first time-dependent signal derived from a first auditory stimulus and a corresponding first measured EEG response; comparing at least part of the first signal with at least part of the first measured EEG response in order to determine a signal-response latency difference; comparing the signal-response latency difference to a reference value; and deriving a measure of speech intelligibility based on the comparison of the signal-response latency difference and the reference value.

IPC Classes  ?

• G10L 21/0364 - Speech enhancement, e.g. noise reduction or echo cancellation by changing the amplitude for improving intelligibility
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

A hybrid graphene material and a filter capable of retaining, in whole or in part, polyaromatic hydrocarbons, carbonyl and other smoke compounds from tobacco products or industrial processes, having as adsorbent substances activated carbon and graphene materials, both supported by the same matrix and in the same filter compartment, which may or may not be attached to another conventional filter compartment of cellulose acetate fibers or similar polymer, and a method for manufacturing such material.

IPC Classes  ?

• C01B 32/198 - Graphene oxide
• A24D 3/16 - Use of materials for tobacco smoke filters of inorganic materials
• B01J 20/00 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof

Abstract

The present disclosure is directed to a multi-species prion protein or peptide thereof, and vaccine compositions comprising the same that are useful for the vaccination and treatment of mammalian subjects at risk of having or having prion disease. Also disclosed herein are isolated proteins and peptides, polymers, vaccines, animal bait or feed, antibodies, and methods of inhibiting the onset of or treating a prion disease.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more secondary therapeutic agents and pharmaceutical compositions thereof.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention relates to methods for improving abiotic stress tolerance (and/or yield) in plants, including enhanced drought tolerance. It discloses nucleic acid constructs comprising the isolated polynucleotides, transgenic plants expressing the same, and methods of using the same for increasing abiotic stress tolerance (and/or yield).

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants

Abstract

Three recombinant E. coli strains produce the enzymes CPD-photolyase, 6,4-bifunctional photolyase and 6,4-photolyase, from bacterial Antarctic isolates of the genus Hymenobacter the first one and Sphingomonas the others. It is also disclosed a process of production and purification of the recombinant enzymes with high performance, high degree of purity and high catalytic repair activity, having applications in, but it is not limited to, cosmetics and pharmaceutical industry. A fast, cheap and qualitative method is provided for the determination of the CPD photolyase activity.

IPC Classes  ?

• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 9/88 - Lyases (4.)
• C12Q 1/527 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving lyase
• C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
• C12N 1/20 - BacteriaCulture media therefor

Abstract

This invention relates to the use of nitroalkene derivatives for the treatment of neurodegenerative conditions in mammals in which neuroinflammation is a contributing factor, such as in amyotrophic lateral sclerosis (ALS).

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/04 - Nitro compounds
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A method of estimating speech intelligibility is disclosed. The method comprises the steps of providing at least a first time-dependent signal derived from a first auditory stimulus and a corresponding first measured EEG response; comparing at least part of the first signal with at least part of the first measured EEG response in order to determine a signal-response latency difference; comparing the signal-response latency difference to a reference value; and deriving a measure of speech intelligibility based on the comparison of the signal-response latency difference and the reference value.

IPC Classes  ?

• A61B 5/12 - Audiometering

Abstract

The invention relates to a hybrid graphene material and a filter able to totally or partially retain polyaromatic hydrocarbons, carbonyl and other compounds from smoke from tobacco products or industrial processes, which has activated carbon and graphene materials as adsorbent substances, both supported by the same matrix and in the same compartment of the filter, which is optionally connected to another compartment of a conventional filter comprising fibres of cellulose acetate or a similar polymer. The invention also relates to a method for producing the material.

IPC Classes  ?

• C01B 32/00 - CarbonCompounds thereof
• A24D 3/16 - Use of materials for tobacco smoke filters of inorganic materials
• B01J 20/00 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof

Abstract

The invention relates to a hybrid graphene material and a filter able to totally or partially retain polyaromatic hydrocarbons, carbonyl and other compounds from smoke from tobacco products or industrial processes, which has activated carbon and graphene materials as adsorbent substances, both supported by the same matrix and in the same compartment of the filter, which is optionally connected to another compartment of a conventional filter comprising fibres of cellulose acetate or a similar polymer. The invention also relates to a method for producing the material.

IPC Classes  ?

• C01B 32/00 - CarbonCompounds thereof
• A24D 3/16 - Use of materials for tobacco smoke filters of inorganic materials
• B01J 20/00 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof

Abstract

The present disclosure is directed to a multi-species prion protein or peptide thereof, and vaccine compositions comprising the same that are useful for the vaccination and treatment of mammalian subjects at risk of having or having prion disease. Also disclosed herein are isolated proteins and peptides, polymers, vaccines, animal bait or feed, antibodies, and methods of inhibiting the onset of or treating a prion disease.

IPC Classes  ?

• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/577 - ImmunoassayBiospecific binding assayMaterials therefor involving monoclonal antibodies

Abstract

The invention comprises a device and method to estimate the elasticity of soft elastic solids from surface wave measurements. The method is non-destructive, reliable and repeatable. The final device is low-cost and portable. It is based in audio-frequency shear wave propagation in elastic soft solids. Within this frequency range, shear wavelength is centimeter sized. Thus, the experimental data is usually collected in the near-field of the source. Therefore, an inversion algorithm taking into account near-field effects was developed for use with the device. Example applications are shown in beef samples, tissue mimicking materials and in vivo skeletal muscle of healthy volunteers.

IPC Classes  ?

• G01N 29/07 - Analysing solids by measuring propagation velocity or propagation time of acoustic waves
• G01N 29/52 - Processing the detected response signal using inversion methods other than spectral analysis, e.g. conjugated gradient inversion
• A61B 5/01 - Measuring temperature of body parts
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• G01C 3/02 - Measuring distances in line of sightOptical rangefinders Details
• G01K 13/00 - Thermometers specially adapted for specific purposes
• G01L 5/00 - Apparatus for, or methods of, measuring force, work, mechanical power, or torque, specially adapted for specific purposes
• G01N 29/24 - Probes
• G01N 29/42 - Detecting the response signal by frequency filtering
• G01N 29/44 - Processing the detected response signal

Abstract

Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more secondary therapeutic agents and pharmaceutical compositions thereof.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method of treating obesity, preventing weight gain, reducing the rate of weight gain, and treating adverse effects related to obesity by administering SANA to induce thermogenesis in a subject.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61P 3/00 - Drugs for disorders of the metabolism
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention provides three recombinant E. coli strains for the production of the enzymes CPD-photolyase, 6,4-bifunctional photolyase and 6,4-photolyase, from bacterial Antarctic isolates of the genus Hymenobacter the first one and Sphingomonas the others. Also provides the process of production and purification of the recombinant enzymes with high performance, high degree of purity and high catalytic repair activity, having applications in, but it is not limited to, cosmetics and pharmaceutical industry. Other aspect of this invention is to provide a fast, cheap and qualitative method for the determination of the CPD-photolyase activity.

IPC Classes  ?

• C12N 9/88 - Lyases (4.)
• C12N 15/60 - Lyases (4)
• C12N 15/70 - Vectors or expression systems specially adapted for E. coli
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12Q 1/527 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving lyase
• C12Q 1/683 - Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
• C12R 1/19 - Escherichia coli
• C12R 1/20 - Flavobacterium

Abstract

Nitroalkene non-steroidal anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of treating inflammation related conditions.

IPC Classes  ?

• C07C 205/17 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups bound to acyclic carbon atoms and hydroxy groups bound to carbon atoms of six-membered aromatic rings
• A61K 31/04 - Nitro compounds
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C07C 205/54 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton

Abstract

Nitroalkene non-steroidal anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of treating inflammation related conditions.

IPC Classes  ?

• C07C 205/17 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups bound to acyclic carbon atoms and hydroxy groups bound to carbon atoms of six-membered aromatic rings
• C07C 205/54 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• A61K 31/04 - Nitro compounds
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The invention relates to methods for improving abiotic stress tolerance (and/or yield)in plants, including enhanced drought tolerance. It discloses nucleic acid constructs comprising the isolated polynucleotides, transgenic plants expressing the same, and methods of using the same for increasing abiotic stress tolerance (and/or yield).

IPC Classes  ?

• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

The invention comprises a device and method to estimate the elasticity of soft elastic solids from surface wave measurements. The method is non-destructive, reliable and repeatable. The final device is low-cost and portable. It is based in audio-frequency shear wave propagation in elastic soft solids. Within this frequency range, shear wavelength is centimeter sized. Thus, the experimental data is usually collected in the near-field of the source. Therefore, an inversion algorithm taking into account near-field effects was developed for use with the device. Example applications are shown in beef samples, tissue mimicking materials and in vivo skeletal muscle of healthy volunteers

IPC Classes  ?

• G01N 29/07 - Analysing solids by measuring propagation velocity or propagation time of acoustic waves
• G01N 29/26 - Arrangements for orientation or scanning

Abstract

Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more second therapeutic agents andpharmaceutical compositions thereof.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more secondary therapeutic agents and pharmaceutical compositions thereof.

IPC Classes  ?

• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial infections. In particular, the present invention relates to a Toll-like receptor (TLR) agonist for use in a method for the treatment of a bacterial infection in a subject in need thereof wherein the TLR agonist is administered to the subject in combination with at least one antibiotic.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/42 - Oxazoles
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of bacterial infections. In particular, the present invention relates to a Toll-like receptor (TLR) agonist for use in a method for the treatment of a bacterial infection in a subject in need thereof wherein the TLR agonist is administered to the subject in combination with at least one antibiotic.

IPC Classes  ?

• A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
• A61K 31/04 - Nitro compounds